Skip to Content

Persantine IV (dipyridamole) Disease Interactions

There are 4 disease interactions with Persantine IV (dipyridamole):

Major

Dipyridamole (applies to Persantine IV) bronchospasm

Major Potential Hazard, Low plausibility. Applicable conditions: Asthma, Chronic Obstructive Pulmonary Disease

Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD). Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.

References

  1. Lette J, Cerino M, Laverdiere M, Tremblay J, Prenovault J "Severe bronchospasm followed by respiratory arrest during thallium- dipyridamole imaging." Chest 95 (1989): 1345-7
  2. "Product Information. Persantine (dipyridamole)." Boehringer-Ingelheim, Ridgefield, CT.
  3. Eagle KA, Boucher CA "Intravenous dipyridamole infusion causes severe bronchospasm in asthmatic patients." Chest 95 (1989): 258-9
Moderate

Dipyridamole (applies to Persantine IV) conduction abnormalities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm. There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block. Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events. Caution is recommended.

Moderate

Dipyridamole (applies to Persantine IV) hypotension

Moderate Potential Hazard, High plausibility.

Dipyridamole can cause peripheral vasodilation. Therapy with dipyridamole should be administered cautiously in patients with hypotension.

References

  1. "Product Information. Persantine (dipyridamole)." Boehringer-Ingelheim, Ridgefield, CT.
  2. Roach PJ, Magee MA, Freedman SB "Asystole and bradycardia during dipyridamole stress testing in patients receiving beta blockers." Int J Cardiol 42 (1993): 92-4
  3. Castello R, Hidalgo R "Dipyridamole-induced myocardial ischemia ." JAMA 259 (1988): 1179
  4. Lo Mauro R, Sabella FP, Enia F "Sinus arrest associated with dipyridamole infusion." Chest 106 (1994): 984
  5. Mauro RL, Sabella FP, Enia F "Sinus arrest associated with dipyridamole infusion." Chest 105 (1994): 604-5
View all 5 references
Moderate

Dipyridamole (applies to Persantine IV) myasthenia gravis

Moderate Potential Hazard, Low plausibility.

Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole. Caution should be exercised with these patients.

References

  1. Nielsen-Kudsk F, Pedersen AK "Pharmacokinetics of dipyridamole." Acta Pharmacol Toxicol (Copenh) 44 (1979): 391-9
  2. Bjornsson TD, Mahony C "Clinical pharmacokinetics of dipyridamole." Thromb Res Suppl 4 (1983): 93-104
  3. "Product Information. Persantine (dipyridamole)." Boehringer-Ingelheim, Ridgefield, CT.
  4. Mahony C, Wolfram KM, Cocchetto DM, Bjornsson TD "Dipyridamol kinetics." Clin Pharmacol Ther 31 (1982): 330-8
View all 4 references

Persantine IV (dipyridamole) drug interactions

There are 149 drug interactions with Persantine IV (dipyridamole)

Persantine IV (dipyridamole) alcohol/food interactions

There are 2 alcohol/food interactions with Persantine IV (dipyridamole)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.